Business Wire
02 Oct 2025, 12:00 UTC · 51w ago
Verdict
Headline takes no side. We score ATXS +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Astria Therapeutics has begun opening clinical trial sites in the European Union for the Phase 3 ALPHA-ORBIT trial of navenibart.
More positive than 78% of claims this week
The company may soon begin screening participants for the navenibart Phase 3 trial for the treatment of hereditary angioedema (HAE).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 65% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The company is advancing its Phase 3 clinical trial by opening sites in the European Union.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
5h ago
+66.8%
Price agrees with the score
$12.58 vs $7.54 close before publication (Oct 1) · not market-adjusted
ATXS chart →
